Ascletis' ASC30 obesity drug shows 75-day half-life in US Study
Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
Launches National IVD validation portal and protocols; highlights India’s strengthening health research ecosystem
Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
He has been associated with the Zydus Group since 2009
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
The company has improved access to quality healthcare for seniors across both urban and rural areas
The AI system was tested on digital slides from breast, colon, stomach, and esophageal cancer cases
AINU is set to accelerate its expansion footprint, enhance operational capabilities
NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India
Subscribe To Our Newsletter & Stay Updated